ArticleScientific reports2024
Spatial discrimination in patients with MSA, PSP, DIP, and VP with pain.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pain is common in Parkinson's disease and frequently observed in other diseases involving parkinsonism. Abnormal scaling function in PD has been reportedly associated with pain, but the role of this function in pain in other parkinsonism-related diseases remains unknown. We screened 127 patients with multiple system atrophy (MSA, n = 24), progressive supranuclear palsy (PSP, n = 15), drug-induced parkinsonism (DIP, n = 56), or vascular parkinsonism (VP, n = 32). After screening, 79 patients with parkinsonism (23 MSA, 10 PSP, 28 DIP, and 18 VP patients) were included in the study. We divided the patients of each group into two groups (with or without pain).The percentages of patients in those groups with pain were 73.9%, 50.0%, 67.9%, and 66.7%, respectively. There was no difference in mean SDT between patients with and without pain in any disease (all p ≥ 0.052). The number of patients showing unmeasurable SDT did not differ between those with and without pain in any disease (all p ≥ 0.316). Our study found no evidence of a role of scaling function in pain development in parkinsonian disorders such as atypical parkinsonism, DIP, and VP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.